Press Releases Ypsomed Group

Burgdorf - Sanofi-Aventis has confirmed the order volumes for calendar year 2008 for the successfully launched and established pen systems: OptiSet, OptiClik and OptiPen Pro. Richard Fritschi, Ypsomed CEO, is pleased: “The confirmed orders for 2008 by Sanofi-Aventis are within our expectations, but - as announced earlier - lower than in the past year.

Burgdorf - Ypsomed is pleased to announce that it has granted to Cilag GmbH International, a non exclusive licence to use certain patents, which protect inventions of Ypsomed, for an autoinjector device for the administration of two biopharmaceutical products with an option to extend the licence for a number of other compounds. Ypsomed is not in a position to communicate the commercial details of the agreement, but expects to receive significant royalties over the term of the contract.

Press Releases Ypsomed Group

Burgdorf - Ypsomed announces that Christoph Brand, Senior Vice President Production & Logistics and member of the Executive Management team leaves the company. Chief Operating Officer Maurice Meytre will take over this responsibility. With immediate effect Hansueli Lehmann as Head of the Solothurn Production site, Benjamin Reinmann as Head of the Burgdorf Production site und Ueli Bracher as Head of Logistics will report directly to Maurice Meytre.

Press Releases Ypsomed Group

Burgdorf - Ypsomed filed a lawsuit against Sanofi-Aventis in Germany. Ypsomed believes that the SoloStar injection system developed and manufactured by Sanofi-Aventis is in breach of its own patents. Sanofi-Aventis uses the SoloStar pen for administration of its Lantus and Apidra insulin products.

Burgdorf - With effect from 1 July 2007 and at a cost of around EUR 11 million (approx. CHF 18 million), Ypsomed has bought 100% of the shares in Florian Müller Holding GmbH, thus providing nationwide coverage in diabetes direct sales and distribution throughout Germany, with the focus on the care of insulin pump patients.